Sunesis Pharmaceuticals, Inc. Receives European Orphan Drug Designation for Vosaroxin to Treat Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the European Commission has granted orphan drug designation to vosaroxin, the Company's lead development candidate, for the treatment of acute myeloid leukemia (AML). The designation provides for 10 years of marketing exclusivity in all EU member countries following product approval. Vosaroxin has previously received orphan drug and fast track designations from the U.S. Food and Drug Administration (FDA).

Back to news